Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Solid Launches Lead Strong Pharma Segment Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.

You may also be interested in...



J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results

Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.

J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results

Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.

J&J’s Consumer Woes Finally Subside As Pharma Continues Strong

The multinational health care company reported significant growth in 2013 that largely was driven by its pharmaceutical division, but bolstered by the resurrection of its long-plagued consumer brands.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS075968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel